Annals of Clinical Microbiology最新文献

{"title":"Clinical usefulness of procalcitonin/albumin and blood urea nitrogen/albumin ratios for the early detection of bacteremia","authors":"Sang-Shin Pyo, Dae Wui Yoon, Hyunjung Kim, H. Chae, Hae Kyung Lee","doi":"10.5145/acm.2023.26.4.103","DOIUrl":"https://doi.org/10.5145/acm.2023.26.4.103","url":null,"abstract":"Background: Early prediction of bacteremia is important because sepsis may develop if bacteremia is not treated in time. We aimed to determine whether blood tests are clinically useful in predicting gram-negative versus gram-positive bacteremia. Methods: We retrospectively analyzed the medical records of 16,569 patients who underwent blood culture testing among those who visited St. Mary’s Hospital of Uijeongbu, Catholic University from January 1, 2018 to December 31, 2018. After excluding 15,580 patients with insufficient data for analysis, the total study population was 989. Results: In the multivariable logistic regression analysis for gram-negative bacteremia, after adjusting for major variables, procalcitonin (odds ratio [OR] 1.02, P < 0.001), high-sensitivity C-reactive protein (OR 1.03, P = 0.010), and albumin (OR 0.55, P = 0.010) were significant. In the same model, lactic acid (OR 1.08, P = 0.010), blood urea nitrogen (BUN) (OR 1.02, P = 0.010), and albumin (OR 0.50, P = 0.005) were significant for gram-positive bacteremia. We constructed blood indicators by combining blood tests that were significant in multivariable logistic regression analysis. Comparing the area under the curve (AUC) of the receiver operating characteristic curve, the AUC of the procalcitonin/albumin ratio in gramnegative bacteremia was significantly higher than that of procalcitonin (0.846 vs. 0.837, P = 0.005), and the AUC of the BUN/albumin ratio in gram-positive bacteremia was significantly higher than that of BUN (0.709 vs. 0.679, P = 0.007). Conclusion: The procalcitonin/albumin ratio is expected to be helpful in the early prediction of gram-negative bacteremia, whereas the BUN/albumin ratio in the early prediction of grampositive bacteremia.","PeriodicalId":34065,"journal":{"name":"Annals of Clinical Microbiology","volume":"103 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138954139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of blood culture data at a university hospital: bacterial distribution and cumulative antimicrobial resistance (2016–2020)","authors":"Y. Seo, Daewon Kim, Hwan Tae Lee, J. Seo, J. Ahn, P. Park","doi":"10.5145/acm.2023.26.4.147","DOIUrl":"https://doi.org/10.5145/acm.2023.26.4.147","url":null,"abstract":"Background: The distribution of bacteria isolated from bloodstream infections and cumulative antimicrobial susceptibility data are the basis for empirical decisions regarding antibiotics as an initial treatment. Therefore, it is important to consistently collect blood culture results of individual patients and analyze them correctly. Methods: The blood culture results of patients at a university hospital from 2016 to 2020 were analyzed retrospectively to determine the bacterial distributions and antibiotic resistance patterns. Duplicates were eliminated by including only the first isolate of each species per patient. Results: Escherichia coli (27.1%) was the most commonly isolated bacterium from blood cultures, followed by Klebsiella pneumoniae (10.1%) and Staphylococcus aureus (8.6%). The methicillin resistance rate of S. aureus was 49.2%, and the vancomycin resistance rate of Enterococcus faecium was 39.5%; with no significant changes over the study period. The cefotaxime, ciprofloxacin, and ertapenem resistance rates of E. coli were 35.0%, 46.8%, and 0.7%, respectively. Seventeen carbapenem-resistant E. coli strains were isolated, of which 11 produced carbapenemase. The cefotaxime, ciprofloxacin, and ertapenem resistance rates of K. pneumoniae were 29.5%, 31.7%, and 5.4%, respectively. Forty-eight carbapenem-resistant K. pneumoniae strains were isolated, of which 37 produced carbapenemase. The imipenem resistance rates of Acinetobacter baumannii and Pseudomonas aeruginosa were 72.3% and 23.4%, respectively. Conclusion: In the blood culture results from 2016 to 2020, the isolation frequency of E. coli, K. pneumoniae, and E. faecium showed an increasing trend, whereas that of S. aureus was stable. Over the 5 year study period, the ciprofloxacin resistance rate of E. coli and P. aeruginosa and ampicillin/sulbactam resistance rate of A. baumannii significantly increased.","PeriodicalId":34065,"journal":{"name":"Annals of Clinical Microbiology","volume":"31 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139169341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative evaluation of critical concentrations for detecting borderline rifampin resistance in Mycobacterium tuberculosis","authors":"Chang-Ki Kim, H. Huh, Jeong Su Park, Taesoung Kim, Jae Han Sohn","doi":"10.5145/acm.2023.26.4.139","DOIUrl":"https://doi.org/10.5145/acm.2023.26.4.139","url":null,"abstract":"Background: Rifampin plays an important role in tuberculosis treatment. In recent years, the introduction of molecular testing techniques has enabled the rapid detection of rifampin resistance, leading to discrepancies with conventional methods. The World Health Organization (WHO) has analyzed mutations in the rpoB gene that induce rifampin resistance and identified certain mutations causing borderline resistance, which are often undetected using conventional tests. Consequently, the WHO has lowered the rifampin resistance criterion concentration from 1.0 to 0.5 μg/mL in 7H10 and MGIT 960. The present study aimed to evaluate the impact of this change in critical concentration on the detection of borderline rifampin resistance in Mycobacterium tuberculosis. Methods: Tuberculosis strains submitted for antituberculosis drug susceptibility testing from May 2021–2022 were analyzed. Three institutions participated; the Seoul Clinical Laboratories used the agar proportion method, whereas the Samsung Medical Center and Seoul National University Bundang Hospital utilized the MGIT 960 system to test both the original and revised concentrations. Mutations were confirmed through rpoB gene sequencing for strains showing discrepancies. Results: A total of 1,596 valid susceptibility tests were conducted during the study period. Rifampin resistance was detected in 35 cases (2.19%) at 1.0 μg/mL and in 38 cases (2.38%) at 0.5 μg/mL, whereas isoniazid resistance was observed in 158 cases (9.90%). Among the three rifampin discrepancy strains, one harbored an H445L mutation, whereas the remaining two exhibited an L452P mutation. These mutations were classified as borderline resistant. Conclusion: Applying the new rifampin critical concentration resulted in a 0.19% increase in resistance rate and an 8.57% increase in detection cases. Additionally, despite testing with large number of rifampin-susceptible strains, no false resistance results were obtained. Therefore, the application of the new critical concentration is considered beneficial for the management of rifampin-resistant tuberculosis.","PeriodicalId":34065,"journal":{"name":"Annals of Clinical Microbiology","volume":"88 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138957957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Trend of Clostridioides difficile Infection in Korean Hospitals with the Analysis of Nationwide Sample Cohort","authors":"Y. A. Kim, K. Son, P. Y. Soo","doi":"10.5145/acm.2020.23.4.3","DOIUrl":"https://doi.org/10.5145/acm.2020.23.4.3","url":null,"abstract":"Background: Clostridioides (Clostridium) difficile is an important pathogen that causes diarrhea in people who take antibiotics. The recent status of C. difficile infection is not well known in Korea. Methods: The long-term trend of C. difficile infection in Korean hospitals was analyzed using a nationwide sample cohort. The data also included sociodemographic characteristics, disease severity, and healthcare facilities. C. difficile infection was defined by the prescription of oral vancomycin or all metronidazole prescriptions under C. difficile infectious disease code (A047). Results: The rate of C. difficile infection has steadily increased from 0.030% in 2006 to 0.317% in The increased rate correlated to age (0.033% for < 50 years,0.421% for 70–79 years, and 0.758% for > 80 years of age) and the Charlson comorbidity index score (0.048% for zero versus 0.378% for three or more points). It differed by the type of medical institution (0.270% at referral hospitals versus 0.056 % at general hospitals and mental hospitals). Conclusion: The rate of C. difficile infection in Korea is significant in patients with advanced age and disease severity. The results show that C. difficile infection trend has been increasing steadily in Korea.","PeriodicalId":34065,"journal":{"name":"Annals of Clinical Microbiology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70970712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fecal Microbiota Transplantation against Gut Colonization Using a Multidrug-Resistant Organism","authors":"Seul Ki Lee, Ji Eun Choi, Chae Min Shin, Mi-Na Kim","doi":"10.5145/acm.2021.24.3.4","DOIUrl":"https://doi.org/10.5145/acm.2021.24.3.4","url":null,"abstract":"Background: Fecal microbiota transplantation against gut colonization using a multidrug-resistant organism is a technique used to treat infections through normalizing the gut microbiota via fecal microbiota transplantation in patients with confirmed colonization by carbapenem-resistant Enterobacteriaceae (CRE) or vancomycin-resistant enterococci (VRE) based on a fecal culture test within the past one week. In this study, we aimed to determine the safety and effectiveness of this technique. Methods: The safety and effectiveness were assessed via a systematic review. A literature search was conducted using five Korean databases, such as KoreaMed, and international databases,including Ovid-MEDLINE, Ovid-EMBASE, and Cochrane Library. Results:Main results are described here. From the studies retrieved using the aforementioned search strategy, the remaining 581 studies were screened using the inclusion and exclusion criteria, resulting in the selection of nine studies for further consideration. In terms of safety, many studies reported deaths and adverse reactions associated with different causes. Fewer studies reported the rate of colonization; however, the effect of colony rate was inconsistent when compared to no treatment group. Additionally, none of the studies assessed the recurrence rate, a decrease in the prevalence of diseases related to infection by multidrug-resistant bacteria, and the quality of life.Conclusion: Fecal bacterial colonization for the decolonization of intestinal multidrug-resistant bacteria was evaluated using a technique that requires further research as there is insufficient literature evidence to validate its safety and efficacy in treating infections through normalizing the intestinal flora of patients with confirmed colonization by CRE or VRE.","PeriodicalId":34065,"journal":{"name":"Annals of Clinical Microbiology","volume":"126 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139320118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SARS-CoV2 Mutation Detection Experience Using PowerChek SARS-CoV-2 S-gene Mutation Detection Kit","authors":"Sun-Mi Cho, Yeon Hee Choi, Seong Geun Hong, Myung Seo Kang","doi":"10.5145/acm.2023.26.3.6","DOIUrl":"https://doi.org/10.5145/acm.2023.26.3.6","url":null,"abstract":"","PeriodicalId":34065,"journal":{"name":"Annals of Clinical Microbiology","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136378537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Introduction to the Revised International Guidelines on Breakpoints for Antimicrobial Susceptibility Testing","authors":"Jae-Woo Chung","doi":"10.5145/acm.2023.26.3.2","DOIUrl":"https://doi.org/10.5145/acm.2023.26.3.2","url":null,"abstract":"Clinical and Laboratory Standards Institute (CLSI) M100 ‘Performance Standards for Antimicrobial Susceptibility Testing (AST)’ and the European Committee on AST (EUCAST) ‘Breakpoint tables for interpretation of MICs and zone diameters’ guidelines for conducting and interpreting AST are revised yearly. The 2023 CLSI guideline introduces selective and cascade reporting methods for antibacterial agents as a part of strengthening antibiotic stewardship and changes in breakpoints for aminoglycoside (AG) in Enterobacterales and AG and piperacillin in Pseudomonas aeruginosa. Main changes in EUCAST include revised breakpoints for aminopenicillins in Enterobacterales, and detailed criteria reflecting the clinical situation and antibacterial agent administration method.","PeriodicalId":34065,"journal":{"name":"Annals of Clinical Microbiology","volume":"164 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136378334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Survey of Physicians’ Perceptions of Diagnostic Tests for Clostridioides difficile Infection","authors":"Hae-Sun Chung, You Sun Kim, Young-Seok Cho, Jeong Su Park, Bo-Moon Shin","doi":"10.5145/acm.2023.26.3.5","DOIUrl":"https://doi.org/10.5145/acm.2023.26.3.5","url":null,"abstract":"Background: This study aimed to investigate perceptions of Clostridioides difficile infection (CDI) diagnostic tests among physicians who prescribe CDI diagnostic tests as part of providing direct patient care. Methods: In August 2018, we provided a 12-question survey of gastroenterologists (the most common referral source for CDI testing) to 35 medical institutions in Korea, asking them about their perceptions of CDI diagnosis and testing. Results: A comparison of the perceptions of physicians and clinical pathologists (CPs) found that physicians had a lower perceived sensitivity of the toxin AB enzyme immunoassay test. For nucleic acid amplification tests, physicians exhibited a perception of higher assay sensitivity and specificity than CPs. The specificity of culture tests was generally perceived as high by physicians, whereas CPs regarding expressed mixed opinions. All but one physician and one CPs found the algorithmic test useful. Concerning the CDI isolation criteria, physicians commenced patient isolation by concurrently assessing both test results and clinical symptoms, rather than exclusively relying upon test results. Among CPs, 84.6% said they could rely on symptoms to determine when to release a patient from isolation, while 46.2% of physicians said they would rely on test results. Conclusion: This study provides useful information on the status of laboratory diagnosis of CDI in Korea and what needs to be improved, which will help to standardize and improve laboratory diagnosis of CDI in Korea.","PeriodicalId":34065,"journal":{"name":"Annals of Clinical Microbiology","volume":"109 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136378536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factor Analysis of Urinary Tract Infection by Cefotaxime-Resistant Escherichia coli and Klebsiella pneumoniae: A Simple and Effective Analysis Using the National Health Insurance Data Sharing Service","authors":"Jae Kwang Lee, Yoonseon Park, Young Ah Kim","doi":"10.5145/acm.2023.26.3.3","DOIUrl":"https://doi.org/10.5145/acm.2023.26.3.3","url":null,"abstract":"Background: This study aims to analyze the risk factors for urinary tract infection (UTI) by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae, using data from the National Health Insurance Data Sharing Service. Methods: A retrospective case-control study was conducted to analyze the risk factors during 11 years (2010–2020). Study groups were selected based on the laboratory data of the hospital, which comprised 3,638 and 877 cases of cefotaxime-resistant E. coli and K. pneumoniae, respectively. Controls comprised 8,994 and 1,573 cases of cefotaxime-nonresistant (intermediate or susceptible) E. coli and K. pneumoniae, respectively. Clinical and socioeconomical features were obtained from the National Health Insurance service data. Results: In a multivariate analysis of risk factors for UTI by cefotaxime-resistant E. coli, the odds ratio (OR) of the male sex was 1.335 (95% confidence interval, 1.204–1.480), age 0–9 years was 1.794 (1.468–2.191), chronic renal disease was 1.227 (1.062–1.417), and hemodialysis was 1.685 (1.255–2.262). Moreover, the ORs of L-tube, central venous pressure catheter, and Foley catheter use were 1.204 (1.047–1.385), 1.332 (1.156–1.534), and 1.473 (1.316–1.649), respectively; the OR of previous antimicrobial use was 1.103 (1.009–1.206) and that of healthcare facility use was 1.782 (1.576–2.014). In a multivariate analysis of risk factors for UTI by cefotaxime-resistant K. pneumoniae, OR of the male sex was 1.460 (1.199–1.778), liver disease was 1.295 (1.037–1.617), and hemodialysis was 2.046 (1.263–3.315). The ORs of L-tube and Foley catheter use were 2.329 (1.861–2.915) and 1.793 (1.431–2.246), respectively, and the OR of the healthcare facility use was 1.545 (1.161–2.056). Original Article Accepted: August 30, 2023 Revised: August 17, 2023 Received: April 24, 2023 https://doi.org/10.5145/ACM.2023.26.3.3 Ann Clin Microbiol 2023 September, 26(2): 59--67 Corresponding author Young Ah Kim E-mail: yakim@nhimc.or.kr Yoonseon Park E-mail: yoonseony@gilhospital.com Jae Kwang Lee, et al. Annals of Clinical Microbiology 2023 September Vol.26(3) 60 Conclusion: In this study, the risk factors for UTI caused by cefotaxime-resistant E. coli or K. pneumoniae were analyzed based on the data of a specific healthcare facility linked to the National Health Insurance system. We suggest that it is a simple and effective way to elucidate risk factors of infections caused by major antimicrobial-resistant pathogens.","PeriodicalId":34065,"journal":{"name":"Annals of Clinical Microbiology","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136378335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Group B Streptococcus Vaccines: Progress and Potential","authors":"Kristin Widyasari, Sunjoo Kim","doi":"10.5145/acm.2023.26.3.1","DOIUrl":"https://doi.org/10.5145/acm.2023.26.3.1","url":null,"abstract":"Group B Streptococcus (GBS, Streptococcus agalactiae) is a pathogen that causes sepsis and meningitis, particularly in newborns, as well as severe infections in the elderly and those at high risk. For many years, the administration of intrapartum antimicrobial prophylaxis (IAP) has been a standard method to prevent neonatal GBS infection. However, IAP may be unsuitable in low-income settings due to its high cost and difficult accessibility to medical institutions. Additionally, IAP may lead to the emergence of antimicrobial-resistant bacteria. Hence, an alternative method for the control of GBS, such as a vaccine, is needed. An effective vaccine will likely prevent the further spread of GBS and be cost-effective compared with IAP. GBS vaccines have been under development for the past two decades, and several candidates have shown potential. In this review, we discuss the current development of GBS vaccines, including types and their implementation in different target populations.","PeriodicalId":34065,"journal":{"name":"Annals of Clinical Microbiology","volume":"187 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136378538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}